Summary
A phase II study of mitoxantrone (Novantrone®; dihydroxyanthracenedione) was conducted in 35 patients (22 male: 13 female) with acute leukemia. There were 35 evaluable cases with a mean age of 34 (range 8–61). Twenty-eight patients had acute non-lymphocytic leukemia (ANLL) and seven had acute lymphocytic leukemia (ALL). Mitoxantrone was administered intravenously 2–4 mg/m2 daily for five days and after the nadir a further 2–3 doses were added if necessary. All previously treated cases (22 patients) had been treated with anthracyclines; 13 had no previous treatment. Out of the 13 untreated cases there were six complete remissions (CRs) (46.2%) and five partial remissions (PRs) (38.5%), while out of 22 pretreated cases, four CRs (18.2%) and five PRs (22.7%) were obtained. In seven of the untreated cases the decrease of leukemic cells and neutrophil leukocytes were analysed. Mitoxantrone showed a longer duration of decrease and higher log decrease of leukemic cells in the bone marrow than daunorubicin or cytosine arabinoside. Seventy-three percent of patients showed gastrointestinal disturbances such as nausea or loss of appetite. In 38.1% SGPT elevation and in 8.8% abnormal ECG findings were observed. All side-effects were mild and reversible. From this data mitoxantrone seems a very promising agent in the treatment of acute leukemia and a phase III study is now being carried out.
Similar content being viewed by others
References
Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF: Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 43:3919–3922, 1983
Estey EH, Keating MJ, McCredie KB, Bodey JG, Freireich EJ: Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67:389–390, 1983
Van Echo DA, Shulman PN, Ferrari A, Budman T, Markus SD, Wiernik PH: A phase II trial of mitoxantrone (DHAD, NSC 301739) in adult acute leukemia. Proc Am Soc Clin Oncol 20:132, 1982
Sanpi K, Honda T, Hayashi Y, Hattori M: Phase II study of mitoxantrone on the hematological malignancy. Jpn J Cancer Chemother 10:1538–1539, 1983 (in Japanese)
Oguma S, Tatsumi Y, Hirayama F, Tani Y, Kubota Y, Kanakura Y, Ueda T, Shibata H, Nakamura H, Masaoka T: Phase II study of mitoxantrone for acute leukemia. Jpn J Cancer Chemother 11:497–501, 1984 (in Japanese)
Kimura K, Kurita S: Chemotherapy of leukemia. Naika 2:262–273, 1983 (in Japanese)
Masaoka T, Hasegawa Y, Ueda T, Takubo T, Shibata H, Nakamura H, Tatsumi N, Yoshitake J, Senda N: On the mode of decrease of leukemic cells during treatment of acute leukemia. Eur J Cancer 12:143–149, 1976
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Masaoka, T., Shibata, H., Oguma, S. et al. A phase II study of mitoxantrone in acute leukemia. Invest New Drugs 3, 197–201 (1985). https://doi.org/10.1007/BF00174170
Issue Date:
DOI: https://doi.org/10.1007/BF00174170